An Israeli group published a paper in JCO this week showing a 40% improvement in survival after two years of maintenance therapy with rituxan. The effect was demonstrated in patients with relapsed low-grade lymphoma but not initial therapy. http://www.reuters.com/article/healthNews/idUSTRE5197J520090210?feedType... Many of these patients go on to have stem cell transplant so it's not clear to me where rituxan fits in.